Skip to main content
×
Home

Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease

  • B. Schmand (a1) (a2), H. M. Huizenga (a2) and W. A. van Gool (a1)
Abstract
Background

Abnormal levels of biomarkers in cerebrospinal fluid (CSF) and atrophy of medial temporal lobe (MTL) structures on magnetic resonance imaging (MRI) are being used increasingly to diagnose early Alzheimer's disease (AD). We evaluated the claim that these biomarkers can detect preclinical AD before behavioural (i.e. memory) symptoms arise.

Method

We included all relevant longitudinal studies of CSF and MRI biomarkers published between January 2003 and November 2008. Subjects were not demented at baseline but some declined to mild cognitive impairment (MCI) or to AD during follow-up. Measures of tau and beta-amyloid in CSF, MTL atrophy on MRI, and performance on delayed memory tasks were extracted from the papers or obtained from the investigators.

Results

Twenty-one MRI studies and 14 CSF studies were retrieved. The effect sizes of total tau (t-tau), phosphorylated tau (p-tau) and amyloid beta 42 (aβ42) ranged from 0.91 to 1.11. The effect size of MTL atrophy was 0.75. Memory performance had an effect size of 1.06. MTL atrophy and memory impairment tended to increase when assessed closer to the moment of diagnosis, whereas effect sizes of CSF biomarkers tended to increase when assessed longer before the diagnosis.

Conclusions

Memory impairment is a more accurate predictor of early AD than atrophy of MTL on MRI, whereas CSF abnormalities and memory impairment are about equally predictive. Consequently, the CSF and MRI biomarkers are not very sensitive to preclinical AD. CSF markers remain promising, but studies with long follow-up periods in elderly subjects who are normal at baseline are needed to evaluate this promise.

Copyright
Corresponding author
*Address for correspondence: B. Schmand, Ph.D., Department of Neurology, H2-222, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands. (Email: b.schmand@amc.uva.nl)
References
Hide All
Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, Lindau M, Eriksdotter-Jonhagen M (2008). Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiology of Aging 29, 14661473.
Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, Mistur R, Tsui WH, de Leon MJ (2008). Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiology of Aging doi:10.1016/j.neurobiolaging.2008.08.008.
Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ (2005). Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology 19, 520531.
Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR (2004). Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 17, 4248.
Blennow K, Hampel H (2003). CSF markers for incipient Alzheimer's disease. Lancet Neurology 2, 605613.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003). Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. British Medical Journal 326, 4144.
Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P (2007). CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiology of Aging 28, 10701074.
Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009). Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiology of Aging 30, 682690.
Buschke H, Sliwinski MJ, Kuslansky G, Lipton RB (1997). Diagnosis of early dementia by the Double Memory Test: encoding specificity improves diagnostic sensitivity and specificity. Neurology 48, 989997.
Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, Quinn JF, Kaye JA (2008). Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 70, 828833.
Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, Lee SE, Lee JY, Aizenstein HJ, Meltzer CC, Liu Y, Toga AW, Becker JT (2007). Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiology of Aging 28, 389397.
Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D, Miller MI, Morris JC (2005). Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. NeuroImage 25, 783792.
Davatzikos C, Fan Y, Wu X, Shen D, Resnick SM (2008). Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging. Neurobiology of Aging 29, 514523.
de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H (2004). MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal of Internal Medicine 256, 205223.
de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H (2007 a). Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Annals of the New York Academy of Sciences 109, 114145.
de Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D (2007 b). Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. Journal of Neurology 254, 16661675.
DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W (2004). Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 63, 220227.
den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM (2006). Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Archives of General Psychiatry 63, 5762.
Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ (2007). Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68, 828836.
Eckerstrom C, Olsson E, Borga M, Ekholm S, Ribbelin S, Rolstad S, Starck G, Edman A, Wallin A, Malmgren H (2008). Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: the Goteborg MCI study. Journal of the Neurological Sciences 272, 4859.
Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, Bouwman FH, Schonknecht P, Schoonenboom NS, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H (2007). Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69, 22052212.
Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007). Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology 64, 343349.
Fellgiebel A, Scheurich A, Bartenstein P, Muller MJ (2007). FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research 155, 167171.
Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr., Aisen PS, Thal LJ (2008). Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70, 191199.
Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A (2008). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging 29, 14561465.
Galton CJ, Erzinclioglu S, Sahakian BJ, Antoun N, Hodges JR (2005). A comparison of the Addenbrooke's Cognitive Examination (ACE), conventional neuropsychological assessment, and simple MRI-based medial temporal lobe evaluation in the early diagnosis of Alzheimer's disease. Cognitive and Behavioral Neurology 18, 144150.
Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, Zanetti O, Frisoni GB (2006). Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. Journal of Neurology, Neurosurgery, and Psychiatry 77, 12191222.
Growdon JH (1999). Biomarkers of Alzheimer disease. Archives of Neurology 56, 281283.
Hall AM, Moore RY, Lopez OL, Kuller L, Becker JT (2008). Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease. Alzheimer's and Dementia 4, 271279.
Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008). Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's and Dementia 4, 3848.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006). Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 5, 228234.
Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttila T (2007). CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiology of Aging 28, 507514.
Herukka SK, Pennanen C, Soininen H, Pirttila T (2008). CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. Journal of Alzheimer's Disease 14, 5157.
Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21, 15391558.
Karas G, Sluimer J, Goekoop R, van der Flier W, Rombouts SA, Vrenken H, Scheltens P, Fox N, Barkhof F (2008). Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR. American Journal of Neuroradiology 29, 944949.
Korf ES, Wahlund LO, Visser PJ, Scheltens P (2004). Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 63, 94100.
Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ (2007). CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69, 631639.
Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C (2002). Visual association test to detect early dementia of the Alzheimer type. Journal of Neurology, Neurosurgery, and Psychiatry 73, 126133.
Maruyama M, Matsui T, Tanji H, Nemoto M, Tomita N, Ootsuki M, Arai H, Sasaki H (2004). Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Archives of Neurology 61, 716720.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939944.
Morris JC, McKeel DW Jr., Fulling K, Torack RM, Berg L (1988). Validation of clinical diagnostic criteria for Alzheimer's disease. Annals of Neurology 24, 1722.
Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ (2007). Early detection of Alzheimer's disease using neuroimaging. Experimental Gerontology 42, 129138.
Neuropathology Group of MRC CFAS (2001). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357, 169175.
Parker RI, Hagan-Burke S (2007). Useful effect size interpretations for single case research. Behavior Therapy 38, 95105.
Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P (2006). Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mechanisms of Ageing and Development 127, 129132.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001). Current concepts in mild cognitive impairment. Archives of Neurology 58, 19851992.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 56, 303308.
Reagan Institute Working Group (1998). Consensus report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer's Disease’. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiology of Aging 19, 109116.
Rosenberg MS, Adams DC, Gurevitch J (2000). MetaWin. Statistical Software for Meta-Analysis. Version 2. Sinauer Associates: Sunderland, MA.
Rosenthal R (1991). Meta-Analytic Procedures for Social Research. Sage: Newbury Park, CA.
Rusinek H, De Santi S, Frid D, Tsui WH, Tarshish CY, Convit A, de Leon MJ (2003). Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 229, 691696.
Schonknecht P, Pantel J, Kaiser E, Thomann P, Schroder J (2007). Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia. Neuroscience Letters 416, 3942.
Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ (2007). Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Reviews Drug Discovery 6, 295303.
Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K (2003). Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dementia and Geriatric Cognitive Disorders 15, 169176.
Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR (2007). Brain structural alterations before mild cognitive impairment. Neurology 68, 12681273.
Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hanninen T, Pihlajamaki M, Laakso MP, Hallikainen M, Hamalainen A, Vanhanen M, Helkala EL, Vanninen R, Nissinen A, Rossi R, Frisoni GB, Soininen H (2008). MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiology of Aging 29, 3138.
Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003). Intrathecal inflammation precedes development of Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 74, 12001205.
Teipel SJ, Born C, Ewers M, Bokde AL, Reiser MF, Moller HJ, Hampel H (2007). Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. NeuroImage 38, 1324.
Thompson SG, Higgins JP (2002). How should meta-regression analyses be undertaken and interpreted? Statistics in Medicine 21, 15591573.
Twamley EW, Ropacki SA, Bondi MW (2006). Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. Journal of the International Neuropsychological Society 12, 707735.
van Houwelingen HC, Arends LR, Stijnen T (2002). Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in Medicine 21, 589624.
Viechtbauer W (2006). MiMa: An S-plus/R Function to Fit Meta-Analytic Mixed-, Random-, and Fixed-Effects Models. Computer software and manual (www.wvbauer.com).
Wang PN, Lirng JF, Lin KN, Chang FC, Liu HC (2006). Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan. Neurobiology of Aging 27, 17971806.
Zaccai J, Ince P, Brayne C (2006). Population-based neuropathological studies of dementia: design, methods and areas of investigation – a systematic review. BMC Neurology 6, 2.
Zakzanis KK (1998). Quantitative evidence for neuroanatomic and neuropsychological markers in dementia of the Alzheimer's type. Journal of Clinical and Experimental Neuropsychology 20, 259269.
Zakzanis KK, Graham SJ, Campbell Z (2003). A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile. Neuropsychological Review 13, 118.
Zamrini E, De Santi S, Tolar M (2004). Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiology of Aging 25, 685691.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 7
Total number of PDF views: 76 *
Loading metrics...

Abstract views

Total abstract views: 296 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th November 2017. This data will be updated every 24 hours.